[go: up one dir, main page]

DK3131533T3 - Oral doseringsform for ketamin - Google Patents

Oral doseringsform for ketamin Download PDF

Info

Publication number
DK3131533T3
DK3131533T3 DK15715764.5T DK15715764T DK3131533T3 DK 3131533 T3 DK3131533 T3 DK 3131533T3 DK 15715764 T DK15715764 T DK 15715764T DK 3131533 T3 DK3131533 T3 DK 3131533T3
Authority
DK
Denmark
Prior art keywords
ketamine
oral dosage
oral
dosage
Prior art date
Application number
DK15715764.5T
Other languages
English (en)
Inventor
Sascha Manthei
Helene Rey
Marc Fischer
Olaf Mundszinger
Original Assignee
Develco Pharma Schweiz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develco Pharma Schweiz Ag filed Critical Develco Pharma Schweiz Ag
Application granted granted Critical
Publication of DK3131533T3 publication Critical patent/DK3131533T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15715764.5T 2014-04-17 2015-04-16 Oral doseringsform for ketamin DK3131533T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14165057 2014-04-17
PCT/EP2015/058318 WO2015158854A1 (en) 2014-04-17 2015-04-16 Oral dosage form of ketamine

Publications (1)

Publication Number Publication Date
DK3131533T3 true DK3131533T3 (da) 2019-09-16

Family

ID=50486823

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17186622.1T DK3272338T3 (da) 2014-04-17 2015-04-16 Oral doseringsform for ketamin
DK15715764.5T DK3131533T3 (da) 2014-04-17 2015-04-16 Oral doseringsform for ketamin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17186622.1T DK3272338T3 (da) 2014-04-17 2015-04-16 Oral doseringsform for ketamin

Country Status (8)

Country Link
US (3) US10335379B2 (da)
EP (4) EP3287124B1 (da)
DK (2) DK3272338T3 (da)
ES (3) ES2935800T3 (da)
FI (1) FI3287124T3 (da)
HU (3) HUE044928T2 (da)
PL (3) PL3287124T3 (da)
WO (1) WO2015158854A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643449A (zh) 2013-03-15 2020-09-11 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3287124B1 (en) * 2014-04-17 2022-11-30 Ketabon GmbH Oral dosage form of ketamine
EP3725307A1 (en) 2014-09-15 2020-10-21 Janssen Pharmaceutica NV Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
CN108884019A (zh) 2016-04-11 2018-11-23 克雷西奥生物科技有限公司 氘代氯胺酮衍生物
US11723883B2 (en) 2017-06-23 2023-08-15 Ketabon Gmbh Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
JP2021529732A (ja) 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
GB2596592A (en) 2020-07-03 2022-01-05 Alkaloid Ad Skopje Pharmaceutical formulation
CN112263572A (zh) * 2020-11-17 2021-01-26 厦门大学附属翔安医院 右旋氯胺酮在制备治疗脱髓鞘疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723614A (en) * 1971-01-06 1973-03-27 Ciba Geigy Ag Maltese-cross scored tablet
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
CN101765582A (zh) 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
US20120225949A1 (en) * 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
WO2014020155A1 (en) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
JP2016531913A (ja) * 2013-08-26 2016-10-13 アモーサ セラピューティックス， インコーポレイテッドＡｍｏｒｓａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 神経抑制性ケタミンの単層による経口投与
EP3287124B1 (en) * 2014-04-17 2022-11-30 Ketabon GmbH Oral dosage form of ketamine

Also Published As

Publication number Publication date
EP3272338A1 (en) 2018-01-24
EP3131533B1 (en) 2019-06-05
ES2829279T3 (es) 2021-05-31
PL3131533T3 (pl) 2019-12-31
ES2743699T3 (es) 2020-02-20
DK3272338T3 (da) 2020-11-02
PL3272338T3 (pl) 2021-01-11
US10335379B2 (en) 2019-07-02
HUE044928T2 (hu) 2019-11-28
PL3287124T3 (pl) 2023-02-20
ES2935800T3 (es) 2023-03-10
WO2015158854A1 (en) 2015-10-22
HUE051264T2 (hu) 2021-03-01
HUE060851T2 (hu) 2023-04-28
EP3287124A1 (en) 2018-02-28
EP3272338B1 (en) 2020-09-09
FI3287124T3 (fi) 2023-01-13
US20170035707A1 (en) 2017-02-09
US11103467B2 (en) 2021-08-31
EP3131533A1 (en) 2017-02-22
US20190290600A1 (en) 2019-09-26
US20210386691A1 (en) 2021-12-16
EP4180030A1 (en) 2023-05-17
EP3287124B1 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
DK3131533T3 (da) Oral doseringsform for ketamin
HUE050732T2 (hu) Új vegyületek
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
LT3134402T (lt) 4-amino-imidazochinolino junginiai
CL2015000439S1 (es) Dispensador
LT3191487T (lt) Katepsino c spirocikliniai inhibitoriai
LT3160952T (lt) Histono demetilazės inhibitoriai
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
BR112016019110A2 (pt) Dispensador
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
FI20145590A (fi) Muuntaja
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
DK3230929T3 (da) Forbedringer til tælleranordninger
DK3126791T3 (da) Doseringsanordning
DK3215223T3 (da) Buprenorphindoseringsskemaer
DK3359555T3 (da) Doseringsplaner
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
DE112015005590A5 (de) Dosierpumpe
EP3628374C0 (en) BCL-3 INHIBITORS
IL249311B (en) You will notice for an oral infection
PL3215437T3 (pl) Urządzenie dozujące
DK3089740T3 (da) Farmaceutisk sammensætning
BR112016027901A2 (pt) Compostos
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม